Introducing DrugInsights, a brand-new clinical publication from IngenioRx. This quarterly newsletter will highlight the latest FDA approvals to arrive on the market. In addition to new molecular entities, our inaugural edition also includes new formulations and indications for existing FDA-approved drugs and biologics.
Q1 2021 DrugInsights
